Cationic lipid:DNA complexes allow bleomycin uptake by melanoma cells.

Area of Science:

• Oncology
• Gene Therapy
• Biotechnology

Background:

• Bleomycin, a chemotherapy drug, has limited cell penetration due to poor diffusion across the plasma membrane.
• Developing strategies to enhance bleomycin delivery and efficacy is crucial for improving cancer treatment outcomes.

Purpose of the Study:

• To evaluate DNA/cationic lipid complexes (lipoplexes) as mediators for enhancing bleomycin uptake and efficacy in canine melanoma cell lines.
• To assess the synergistic effects of combining bleomycin with lipoplexes in different cellular configurations (monolayers and spheroids).

Main Methods:

• Utilized four spontaneous canine melanoma cell lines (Ak, Bk, Br, Rkb).
• Assessed cell survival using the acid phosphatase method post-lipofection with or without bleomycin.
• Quantified cellular uptake of lipoplexes carrying the E. coli β-galactosidase gene via SYBR Green I staining.

Main Results:

• The bleomycin/lipoplexes system demonstrated significant sensitivity across all four cell lines in both monolayer and spheroid models.
• Survival rates were below 20% in monolayers and below 30% in spheroids for most cell lines.
• Lipoplexes sensitized resistant cell lines (Ak, Rkb) to bleomycin, reducing the drug's IC50 by 10-fold in monolayers and sensitizing resistant spheroids.
• Bleomycin's cytotoxic effects were dependent on lipoplex concentration and temperature, suggesting an active uptake mechanism like endocytosis.

Conclusions:

• Lipoplexes effectively sensitize canine melanoma cells to bleomycin, enhancing drug uptake through an active transport mechanism.
• The combination of bleomycin with lipoplexes represents a promising strategy for non-viral cancer gene therapy and chemotherapy.
• This approach holds potential for improving the efficacy of bleomycin treatment in challenging cancer models.